FDA requests removal of suicidal ideation warnings from GLP-1 RA labels after meta-analysis shows no increased risk compared with placebo.

HealthDay News — Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with a reduced risk for colorectal cancer (CRC) incidence compared with aspirin, according to a study presented ...

The risks for disease progression and death were lower for patients with stage 3b or higher CKD receiving GLP-1 RA vs DPP4i. Real-world data show that treatment with glucagon-like peptide-1 receptor ...

Over half of semaglutide users in Denmark discontinued within a year, with significant drop-off rates at 3, 6, and 9 months. High costs, lack of insurance coverage, and adverse effects contribute to ...

Weight loss drugs known as GLP-1 receptor agonists are sometimes referred to as “miracle drugs,” not only because they help people lose weight, but because they’ve also been shown to help with many ...

An analysis uncovered racial, ethnic, and socioeconomic inequities regarding access to glucagon-like peptide-1 receptor agonists among US patients with diabetes. Racial, ethnic, and socioeconomic ...

In a recent study published in the JAMA Network Open, a group of researchers evaluated the impact of exercise, glucagon-like peptide-1 receptor agonist (GLP-1 RA) liraglutide, and their combination on ...

People with Type 2 diabetes who combined healthy lifestyle habits with GLP-1 receptor agonist (GLP-1 RA) medications had a greater reduction in risk of major adverse cardiovascular events, including ...

A more detailed review of data by the FDA showed that GLP-1 drugs do not increase the risk of suicidal ideation or behavior.